These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12062390)

  • 1. Liposomal encapsulation enhances antiviral efficacy of SPC3 against human immunodeficiency virus type-1 infection in human lymphocytes.
    de Mareuil J; Mabrouk K; Doria E; Moulard M; de Chasteigner S; Oughideni R; van Rietschoten J; Rochat H; De Waard M; Sabatier JM
    Antiviral Res; 2002 Jun; 54(3):175-88. PubMed ID: 12062390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of antiviral activity with beta-turn types for V3 synthetic multibranched peptides from HIV-1 gp120.
    Mabrouk K; Van Rietschoten J; Rochat H; Loret EP
    Biochemistry; 1995 Jul; 34(26):8294-8. PubMed ID: 7599121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.
    Yahi N; Fantini J; Baghdiguian S; Mabrouk K; Tamalet C; Rochat H; Van Rietschoten J; Sabatier JM
    Proc Natl Acad Sci U S A; 1995 May; 92(11):4867-71. PubMed ID: 7761414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. V3 loop-derived peptide SPC3 inhibits infection of CD4- and galactosylceramide- cells by LAV-2/B.
    Moulard M; Mabrouk K; Martin I; Van Rietschoten J; Rochat H; Sabatier JM
    J Pept Res; 1999 Jun; 53(6):647-55. PubMed ID: 10408339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPC3, an anti-HIV peptide construct derived from the viral envelope, binds and enters HIV target cells.
    Barbouche R; Miquelis R; Sabatier JM; Fenouillet E
    J Pept Sci; 1998 Dec; 4(8):479-85. PubMed ID: 9927254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.
    Delézay O; Hammache D; Fantini J; Yahi N
    Biochemistry; 1996 Dec; 35(49):15663-71. PubMed ID: 8961929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of a hydrophobic tripeptide on human immunodeficiency virus type 1 (HIV-1)-induced syncytium formation and viral infectivity.
    Konopka K; Pretzer E; Düzgünes N
    Biochem Biophys Res Commun; 1995 Mar; 208(1):75-81. PubMed ID: 7887968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ion channel activation by SPC3, a peptide derived from the HIV-1 gp120 V3 loop.
    Carlier E; Mabrouk K; Moulard M; Fajloun Z; Rochat H; De Waard M; Sabatier JM
    J Pept Res; 2000 Dec; 56(6):427-37. PubMed ID: 11152302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials.
    Barbouche R; Fenouillet E; Papandréou MJ; Kiény MP; Sabatier JM
    J Pept Res; 1998 Oct; 52(4):283-8. PubMed ID: 9832306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics.
    Dusserre N; Lessard C; Paquette N; Perron S; Poulin L; Tremblay M; Beauchamp D; Désormeaux A; Bergeron MG
    AIDS; 1995 Aug; 9(8):833-41. PubMed ID: 7576316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of HIV type 1 replication by simultaneous infection of peripheral blood lymphocytes with human immunodeficiency virus types 1 and 2.
    Dern K; Rübsamen-Waigmann H; Unger RE
    AIDS Res Hum Retroviruses; 2001 Mar; 17(4):295-309. PubMed ID: 11242517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The antiviral action of recombinant forms of the human T-lymphocyte CD4 receptor].
    Zverev VV; Maliushova VV; Sidorov AV; Pugach AV; Shukhmina NR; Pille ER; Mel'nikova NL; Andzhaparidze OG
    Vopr Virusol; 1994; 39(2):56-9. PubMed ID: 7517083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPC3, a nontoxic peptide inhibitor of HIV infection.
    Sabatier JM; Baghdiguian S; Yahi N; Rochat H; Van Rietschoten J; Fantini J
    In Vitro Cell Dev Biol Anim; 1995 Jun; 31(6):415-8. PubMed ID: 8589880
    [No Abstract]   [Full Text] [Related]  

  • 14. Increase in sensitivity to soluble CD4 by primary HIV type 1 isolates after passage through C8166 cells: association with sequence differences in the first constant (C1) region of glycoprotein 120.
    Orloff SL; Bandea CI; Kennedy MS; Allaway GP; Maddon PJ; McDougal JS
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):335-42. PubMed ID: 7786580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
    Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human immunodeficiency virus type-1 replication in macrophages and H9 cells by free or liposome-encapsulated L-689,502, an inhibitor of the viral protease.
    Pretzer E; Flasher D; Düzgüneş N
    Antiviral Res; 1997 Mar; 34(1):1-15. PubMed ID: 9107381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear localization signal of HIV-1 as a novel target for therapeutic intervention.
    Dubrovsky L; Ulrich P; Nuovo GJ; Manogue KR; Cerami A; Bukrinsky M
    Mol Med; 1995 Jan; 1(2):217-30. PubMed ID: 8529100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by daphnodorins.
    Yusa K; Oh-hara T; Tsukahara S; Baba K; Taniguchi M; Kozawa M; Takeuchi S; Hara H; Tsuruo T
    Antiviral Res; 1994 Sep; 25(1):57-66. PubMed ID: 7529015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-HIV activity of multibranched peptide constructs derived either from the cleavage sequence or from the transmembrane domain (gp41) of the human immunodeficiency virus type 1 envelope.
    Sabatier JM; Mabrouk K; Moulard M; Rochat H; Van Rietschoten J; Fenouillet E
    Virology; 1996 Sep; 223(2):406-8. PubMed ID: 8806580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes.
    Clayton R; Ohagen A; Nicol F; Del Vecchio AM; Jonckers TH; Goethals O; Van Loock M; Michiels L; Grigsby J; Xu Z; Zhang YP; Gutshall LL; Cunningham M; Jiang H; Bola S; Sarisky RT; Hertogs K
    Antiviral Res; 2009 Nov; 84(2):142-9. PubMed ID: 19699239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.